Racial disparities in hepatocellular carcinoma: a TCGA-based gene expression study of Caucasian and Asian populations

Muhammad Rezki Rasyak , Sri Jayanti , Cyrollah Disoma , Bens Pardamean , Caecilia Sukowati

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002344

PDF (5029KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002344 DOI: 10.37349/etat.2025.1002344
Original Article
research-article
Racial disparities in hepatocellular carcinoma: a TCGA-based gene expression study of Caucasian and Asian populations
Author information +
History +
PDF (5029KB)

Abstract

Aim: Hepatocellular carcinoma (HCC) displays both shared and ethnicity-specific molecular characteristics. Using transcriptomic data from The Cancer Genome Atlas (TCGA), we compared gene expression profiles between Asian and Caucasian HCC patients.

Methods: Gene expression profiles were analyzed using the PyDESeq2 implementation of DESeq2, applying size factor normalization and dispersion estimation. Differentially expressed genes (DEGs) were identified with thresholds of false discovery rate (FDR) of < 0.05 and |log2FC| ≥ 1.0. Gene annotation, visualization, and pathway enrichment were conducted using Sanbomics, seaborn, and gene set enrichment analysis (GSEA) via the GSEApy package.

Results: A total of 387 and 250 genes were commonly upregulated and downregulated, respectively, in both populations, including the upregulations of GPC3 and PLVAP and the downregulations of FCN3 and OIT3, indicating their potential as universal HCC markers. Conversely, 16 genes were upregulated in Asians but downregulated in Caucasians, and 25 showed the reverse pattern. Asian-specific upregulation of AKR1B10, UBE2C, and S100P suggests links to viral etiology and immune modulation, while MDK, LCN2, and NQO1 were upregulated in Caucasians, implicating proliferative and metabolic roles. Functional enrichment analysis revealed distinct immune and metabolic pathways. Asians showed elevated ubiquitin ligase activity and suppressed inflammatory responses, while Caucasians exhibited enhanced cytokine signaling, complement activation, and xenobiotic metabolism.

Conclusions: These findings highlight key molecular differences in HCC across ethnicities and emphasize the value of TCGA data for identifying both shared targets and population-specific therapeutic strategies. Understanding these differences is crucial for advancing precision oncology and developing tailored interventions.

Keywords

hepatocellular carcinoma / gene expression / populations / TCGA

Cite this article

Download citation ▾
Muhammad Rezki Rasyak, Sri Jayanti, Cyrollah Disoma, Bens Pardamean, Caecilia Sukowati. Racial disparities in hepatocellular carcinoma: a TCGA-based gene expression study of Caucasian and Asian populations. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002344 DOI:10.37349/etat.2025.1002344

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer. 2024; 24: 62-70.

[2]

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229-63.

[3]

GBD US Health Disparities Collaborators. Burden of liver cancer mortality by county, race, and ethnicity in the USA, 2000-19: a systematic analysis of health disparities. Lancet Public Health. 2024; 9: e186-98.

[4]

Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021; 12: S361-73.

[5]

Kim NJ, Cravero A, VoPham T, Vutien P, Carr R, Issaka RB, et al. Addressing racial and ethnic disparities in US liver cancer care. Hepatol Commun. 2023; 7:e00190.

[6]

Vidal AC, Moylan CA, Wilder J, Grant DJ, Murphy SK, Hoyo C. Racial disparities in liver cancer: Evidence for a role of environmental contaminants and the epigenome. Front Oncol. 2022; 12: 959852.

[7]

Varghese RS, Barefoot ME, Jain S, Chen Y, Zhang Y, Alley A, et al. Integrative Analysis of DNA Methylation and microRNA Expression Reveals Mechanisms of Racial Heterogeneity in Hepatocellular Carcinoma. Front Genet. 2021; 12: 708326.

[8]

Duan X, Cai Y, He T, Shi X, Zhao J, Zhang H, et al. The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds. J Gastrointest Oncol. 2021; 12: 1786-96.

[9]

Wen GM, Song CL, Liu DH, Xia P. Different races have different immune microenvironments: comparison of White and Asian patients with liver cancer. Am J Cancer Res. 2023; 13: 1118-27.

[10]

Cancer Genome Atlas Research Network; Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013; 45: 1113-20.

[11]

Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017; 169: 1327-41.e23.

[12]

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15: 550.

[13]

The GTEx Consortium; Ardlie KG, Deluca DS, Segrè AV, Sullivan TJ, Young TR, Gelfand ET, et al. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015; 348: 648-60.

[14]

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45: W98-102.

[15]

Zhou F, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018; 38: 741-67.

[16]

Wang Y, Cheng T, Chen T, Chang K, Chuang VP, Kao K. Plasmalemmal Vesicle Associated Protein (PLVAP) as a therapeutic target for treatment of hepatocellular carcinoma. BMC Cancer. 2014; 14: 815.

[17]

Zheng G, Wu L, Bouamar H, Cserhati M, Chiu Y, Hinck CS, et al. Ficolin-3 induces apoptosis and suppresses malignant property of hepatocellular carcinoma cells via the complement pathway. Life Sci. 2024; 357: 123103.

[18]

Yang S, Zhang J, Xu Y, Wang J, Zhao H, Lei J, et al. OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression. Cancer Immunol Immunother. 2022; 71: 2677-89.

[19]

Wu A, Li H, Gao M, Liang J, Huang J, Farrés J, et al. The pan-cancer landscape of aldo-keto reductase1B10 reveals that its expression is diminished in gastric cancer. Front Immunol. 2024; 15: 1488042.

[20]

Semmo N, Weber T, Idle JR, Beyoğlu D. Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection. J Viral Hepat. 2015; 22: 617-24.

[21]

Mori M, Genda T, Ichida T, Murata A, Kamei M, Tsuzura H, et al. Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk. Hepatol Res. 2017; 47: E85-93.

[22]

Zhan P, Lu Y, Lu J, Cheng Y, Luo C, Yang F, et al. The activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma. Sci Rep. 2024; 14: 22859.

[23]

Singh P, Ali SA. Multifunctional Role of S100 Protein Family in the Immune System: An Update. Cells. 2022; 11: 2274.

[24]

Xu B, Lv W, Li X, Zhang L, Lin J. Prognostic genes of hepatocellular carcinoma based on gene coexpression network analysis. J Cell Biochem. 2019; 120: 11616-23.

[25]

Basbous S, Paysan L, Sena S, Allain N, Hiriart J, Dugot-Senant N, et al. Silencing of RND3/RHOE inhibits the growth of human hepatocellular carcinoma and is associated with reversible senescence. Cancer Gene Ther. 2022; 29: 437-44.

[26]

Yang Z, Deng X, Wen D, Sun L, An R, Xu J. Identification of RCAN1ʼs role in hepatocellular carcinoma using single-cell analysis. BMC Cancer. 2024; 24: 1056.

[27]

Luong AB, Do HQ, Tarchi P, Bonazza D, Bottin C, Cabral LKD, et al. The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations. Cells. 2020; 9: 2672.

[28]

Wang X, Liu Y, Han A, Tang C, Xu R, Feng L, et al. The NQO1/p53/SREBP1 axis promotes hepatocellular carcinoma progression and metastasis by regulating Snail stability. Oncogene. 2022; 41: 5107-20.

[29]

Christou C, Stylianou A, Gkretsi V. Midkine (MDK) in Hepatocellular Carcinoma: More than a Biomarker. Cells. 2024; 13: 136.

[30]

Han B, An Z, Gong T, Pu Y, Liu K. LCN2 Promotes Proliferation and Glycolysis by Activating the JAK2/STAT3 Signaling Pathway in Hepatocellular Carcinoma. Appl Biochem Biotechnol. 2024; 196: 717-28.

[31]

Ashida R, Okamura Y, Ohshima K, Kakuda Y, Uesaka K, Sugiura T, et al. The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma. Oncotarget. 2018; 9: 22058-68.

[32]

Link F, Li Y, Zhao J, Munker S, Fan W, Nwosu ZC, et al. ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-β1 activation. Gut. 2025; 74: 424-39.

[33]

Ye Y, Wang G, Wang G, Zhuang J, He S, Song Y, et al. The Oncogenic Role of Tribbles 1 in Hepatocellular Carcinoma Is Mediated by a Feedback Loop Involving microRNA-23a and p53. Front Physiol. 2017; 8: 789.

[34]

Huang L, Hsieh T, Huang C, Liu Y, Wu S, Chien P, et al. Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations. Genes (Basel). 2021; 12: 1274.

[35]

Kawamura A, Matsuda K, Murakami Y, Saruta M, Kohno T, Shiraishi K. Contribution of an Asian-prevalent HLA haplotype to the risk of HBV-related hepatocellular carcinoma. Sci Rep. 2023; 13: 12944.

[36]

Rouleau M, Schwab M, Klein K, Tremmel R, Haag M, Schaeffeler E, et al. The liver proteome of individuals with a natural UGT2B17 complete deficiency. Sci Rep. 2025; 15: 5458.

[37]

Kaya NA, Chen J, Lai H, Yang H, Ma L, Liu X, et al. Genome instability is associated with ethnic differences between Asians and Europeans in hepatocellular carcinoma. Theranostics. 2022; 12: 4703-17.

[38]

Chen K, Shuen TWH, Chow PKH. The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications. Br J Cancer. 2024; 131: 420-9.

[39]

Zheng X, Yang L, Shen X, Pan J, Chen Y, Chen J, et al. Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2024; 12: e009642.

[40]

Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023; 14: 1133308.

[41]

Khamis ZI, Pang X, Cui Z, Sang QA, Zhang J. Cytochrome P450-2D6: A novel biomarker in liver cancer health disparity. PLoS One. 2021; 16: e0257072.

[42]

Wu H, Liu Y, Liu Q, Li Z, Wan Y, Cao C, et al. HMMR triggers immune evasion of hepatocellular carcinoma by inactivation of phagocyte killing. Sci Adv. 2024; 10: eadl6083.

PDF (5029KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉